These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 17409804)

  • 21. Treatment of malignant pleural mesothelioma with liposomized doxorubicine: prolonged time to progression and good survival. A Nordic study.
    Hillerdal G; Sorensen JB; Sundström S; Vikström A; Hjerpe A
    Clin Respir J; 2008 Apr; 2(2):80-5. PubMed ID: 20298311
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase I and pharmacokinetic study of 10-propargyl-10-deazaaminopterin, a new antifolate.
    Krug LM; Ng KK; Kris MG; Miller VA; Tong W; Heelan RT; Leon L; Leung D; Kelly J; Grant SC; Sirotnak FM
    Clin Cancer Res; 2000 Sep; 6(9):3493-8. PubMed ID: 10999734
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.
    Govindan R; Kratzke RA; Herndon JE; Niehans GA; Vollmer R; Watson D; Green MR; Kindler HL;
    Clin Cancer Res; 2005 Mar; 11(6):2300-4. PubMed ID: 15788680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Irinotecan for malignant mesothelioma A phase II trial by the Cancer and Leukemia Group B.
    Kindler HL; Herndon JE; Zhang C; Green MR;
    Lung Cancer; 2005 Jun; 48(3):423-8. PubMed ID: 15893012
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Palliative and therapeutic activity of IL-2 immunotherapy in unresectable malignant pleural mesothelioma with pleural effusion: Results of a phase II study on 31 consecutive patients.
    Castagneto B; Zai S; Mutti L; Lazzaro A; Ridolfi R; Piccolini E; Ardizzoni A; Fumagalli L; Valsuani G; Botta M
    Lung Cancer; 2001; 31(2-3):303-10. PubMed ID: 11165411
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 10-propargyl-10-deazaaminopterin: an antifolate with activity in patients with previously treated non-small cell lung cancer.
    Krug LM; Azzoli CG; Kris MG; Miller VA; Khokhar NZ; Tong W; Ginsberg MS; Venkatraman E; Tyson L; Pizzo B; Baez V; Ng KK; Sirotnak FM
    Clin Cancer Res; 2003 Jun; 9(6):2072-8. PubMed ID: 12796370
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A phase I clinical pharmacologic study of pralatrexate in combination with probenecid in adults with advanced solid tumors.
    Fury MG; Krug LM; Azzoli CG; Sharma S; Kemeny N; Wu N; Kris MG; Rizvi NA
    Cancer Chemother Pharmacol; 2006 May; 57(5):671-7. PubMed ID: 16136310
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Malignant pleural mesothelioma: surgical management in 285 patients.
    Schipper PH; Nichols FC; Thomse KM; Deschamps C; Cassivi SD; Allen MS; Pairolero PC
    Ann Thorac Surg; 2008 Jan; 85(1):257-64; discussion 264. PubMed ID: 18154820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma.
    Ceresoli GL; Zucali PA; Favaretto AG; Grossi F; Bidoli P; Del Conte G; Ceribelli A; Bearz A; Morenghi E; Cavina R; Marangolo M; Parra HJ; Santoro A
    J Clin Oncol; 2006 Mar; 24(9):1443-8. PubMed ID: 16549838
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Morbidity, mortality, mean survival, and the impact of histology on survival after pleurectomy in 64 patients with malignant pleural mesothelioma.
    Neragi-Miandoab S; Richards WG; Sugarbaker DJ
    Int J Surg; 2008 Aug; 6(4):293-7. PubMed ID: 18585112
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Brief report: a phase II study of sunitinib in malignant pleural mesothelioma. the NCIC Clinical Trials Group.
    Laurie SA; Gupta A; Chu Q; Lee CW; Morzycki W; Feld R; Foo AH; Seely J; Goffin JR; Laberge F; Murray N; Rao S; Nicholas G; Laskin J; Reiman T; Sauciuc D; Seymour L
    J Thorac Oncol; 2011 Nov; 6(11):1950-4. PubMed ID: 22005473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose ifosfamide with mesna and granulocyte-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma.
    Talbot SM; Rankin C; Taub RN; Balcerzak SP; Bhoopalam N; Chapman RA; Baker LH; Middleman EL; Antman KH
    Cancer; 2003 Jul; 98(2):331-6. PubMed ID: 12872353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase II study evaluating the cisplatin and epirubicin combination in patients with unresectable malignant pleural mesothelioma.
    Berghmans T; Lafitte JJ; Paesmans M; Stach B; Berchier MC; Wackenier P; Lecomte J; Collon T; Mommen P; Sculier JP;
    Lung Cancer; 2005 Oct; 50(1):75-82. PubMed ID: 16005104
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pemetrexed and cisplatin for malignant pleural mesothelioma: a new standard of care?
    Rusch VW
    J Clin Oncol; 2003 Jul; 21(14):2629-30. PubMed ID: 12860935
    [No Abstract]   [Full Text] [Related]  

  • 35. Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052).
    O'Brien ME; Gaafar RM; Popat S; Grossi F; Price A; Talbot DC; Cufer T; Ottensmeier C; Danson S; Pallis A; Hasan B; Van Meerbeeck JP; Baas P
    Eur J Cancer; 2013 Sep; 49(13):2815-22. PubMed ID: 23791541
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase I study of extrapleural pneumonectomy and intracavitary intraoperative hyperthermic cisplatin with amifostine cytoprotection for malignant pleural mesothelioma.
    Zellos L; Richards WG; Capalbo L; Jaklitsch MT; Chirieac LR; Johnson BE; Bueno R; Sugarbaker DJ
    J Thorac Cardiovasc Surg; 2009 Feb; 137(2):453-8. PubMed ID: 19185169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single-arm, open label study of pemetrexed plus cisplatin in chemotherapy naïve patients with malignant pleural mesothelioma: outcomes of an expanded access program.
    Obasaju CK; Ye Z; Wozniak AJ; Belani CP; Keohan ML; Ross HJ; Polikoff JA; Mintzer DM; Monberg MJ; Jänne PA;
    Lung Cancer; 2007 Feb; 55(2):187-94. PubMed ID: 17092602
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemotherapy of malignant pleural mesothelioma: have we made any progress?].
    Reck M; Heigener DF; Gatzemeier U
    Zentralbl Chir; 2008 Jun; 133(3):238-42. PubMed ID: 18563688
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High-dose methotrexate in combination with interferons in the treatment of malignant pleural mesothelioma.
    Halme M; Knuuttila A; Vehmas T; Tammilehto L; Mäntylä M; Salo J; Mattson K
    Br J Cancer; 1999 Aug; 80(11):1781-5. PubMed ID: 10468296
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma.
    Trafalis DT; Alifieris C; Krikelis D; Tzogkas N; Stathopoulos GP; Athanassiou AE; Sitaras NM
    Int J Clin Pharmacol Ther; 2012 Jul; 50(7):490-9. PubMed ID: 22578202
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.